The gut microbiome regulates the clinical efficacy of sulfasalazine therapy for IBD-associated spondyloarthritis

• DOI: 10.1016/j.xcrm.2024.101431
• Publication Date: 2024-02-19T15:31:49Z
• Authors: Svetlana F. Lima; Silvia Pires; Amanda Rupert; Seun Oguntunmibi; Wen-Bing Jin; Andrew Marderstein; Gabriela Funez-de...; Grace Maldarelli; Monica Viladomiu; Gregory Putzel; Wei Yang; Nancy Tran; Grace Xiang; Alex Grier; Chun-Jun Guo; Dana Lukin; Lisa A. Mandl; Ellen J. Scherl; Randy S. Longman
• Keywords: Sulfasalazine; Faecalibacterium prausnitzii; Sulfapyridine

Sulfasalazine is a prodrug known to be effective for the treatment of inflammatory bowel disease (IBD)-associated peripheral spondyloarthritis (pSpA), but mechanistic role gut microbiome in regulating its clinical efficacy not well understood. Here, 22 IBD-pSpA subjects with sulfasalazine identifies responders enriched Faecalibacterium prausnitzii and capacity butyrate production. Sulfapyridine promotes production transcription synthesis gene F. vitro, which suppressed by excess folate. therapy enhances fecal limits colitis wild-type gnotobiotic mice colonized responder, non-responder, microbiomes. sufficient restore protection from non-responder These findings reveal link between potential guide diagnostic therapeutic approaches IBD-pSpA.